中华脑血管病杂志（电子版）
中華腦血管病雜誌（電子版）
중화뇌혈관병잡지（전자판）
CHINESE JOURNAL OF CEREBROVASCULAR DISEASES(ELECTRONIC VERSION)
2012年
2期
26-30
,共5页
脑梗死%高迁移率族蛋白B1%骨保护素%巨噬细胞移动抑制因子%动脉粥样硬化%阿托伐他汀%普罗布考
腦梗死%高遷移率族蛋白B1%骨保護素%巨噬細胞移動抑製因子%動脈粥樣硬化%阿託伐他汀%普囉佈攷
뇌경사%고천이솔족단백B1%골보호소%거서세포이동억제인자%동맥죽양경화%아탁벌타정%보라포고
Cerebral infarction%High-mobility group box 1 protein%Osteoprotegerin%Macrophage migration inhibitory factor%Atherosclerosis%Atorvastatin%Probucol
目的 探讨急性脑梗死患者血清高迁移率族蛋白BI( HMGB1)、骨保护素(OPG)及巨噬细胞移动抑制因子(MIF)水平的变化以及普罗布考、阿司匹林、他汀类药物(PAS)三联疗法对其干预作用.方法 选择150例急性脑梗死患者,根据颈动脉超声检查结果分为颈动脉稳定斑块组(50例)和颈动脉易损斑块组(100例).将稳定斑块组作为对照组,易损斑块组抽血检查后按随机数字法分为AS组50例(阿司匹林100 mg/d,阿托伐他汀20 mg/d,口服)和PAS组50例(阿司匹林100 mg/d,阿托伐他汀20 mg/d,普罗布考0.25/次,2次／d,口服).比较治疗前和治疗后4周血清HMGB1、OPG和MIF水平.结果 治疗前,易损斑块组中两亚组血清HMGB1、OPG和MIF含量均明显高于稳定斑块组,差异有显著统计学意义(均P＜0.01)；两亚组中血清HMGB1、OPG和MIF含量差异无统计学意义(均P＞0.05).治疗后4周,PAS组中血清HMGB1,OPG和MIF含量均明显低于AS组,且各指标下降幅度均高于AS组,差异有显著统计学意义(均P＜0.01).结论 血清HMGB1、OPG和MIF均参与脑梗死患者动脉粥样硬化的进程,可作为评估颈动脉粥样硬化斑块不稳定性的预测因子,PAS三联疗法可有效降低其血清浓度,具有更强的抗炎作用,可提高易损斑块的稳定性.
目的 探討急性腦梗死患者血清高遷移率族蛋白BI( HMGB1)、骨保護素(OPG)及巨噬細胞移動抑製因子(MIF)水平的變化以及普囉佈攷、阿司匹林、他汀類藥物(PAS)三聯療法對其榦預作用.方法 選擇150例急性腦梗死患者,根據頸動脈超聲檢查結果分為頸動脈穩定斑塊組(50例)和頸動脈易損斑塊組(100例).將穩定斑塊組作為對照組,易損斑塊組抽血檢查後按隨機數字法分為AS組50例(阿司匹林100 mg/d,阿託伐他汀20 mg/d,口服)和PAS組50例(阿司匹林100 mg/d,阿託伐他汀20 mg/d,普囉佈攷0.25/次,2次／d,口服).比較治療前和治療後4週血清HMGB1、OPG和MIF水平.結果 治療前,易損斑塊組中兩亞組血清HMGB1、OPG和MIF含量均明顯高于穩定斑塊組,差異有顯著統計學意義(均P＜0.01)；兩亞組中血清HMGB1、OPG和MIF含量差異無統計學意義(均P＞0.05).治療後4週,PAS組中血清HMGB1,OPG和MIF含量均明顯低于AS組,且各指標下降幅度均高于AS組,差異有顯著統計學意義(均P＜0.01).結論 血清HMGB1、OPG和MIF均參與腦梗死患者動脈粥樣硬化的進程,可作為評估頸動脈粥樣硬化斑塊不穩定性的預測因子,PAS三聯療法可有效降低其血清濃度,具有更彊的抗炎作用,可提高易損斑塊的穩定性.
목적 탐토급성뇌경사환자혈청고천이솔족단백BI( HMGB1)、골보호소(OPG)급거서세포이동억제인자(MIF)수평적변화이급보라포고、아사필림、타정류약물(PAS)삼련요법대기간예작용.방법 선택150례급성뇌경사환자,근거경동맥초성검사결과분위경동맥은정반괴조(50례)화경동맥역손반괴조(100례).장은정반괴조작위대조조,역손반괴조추혈검사후안수궤수자법분위AS조50례(아사필림100 mg/d,아탁벌타정20 mg/d,구복)화PAS조50례(아사필림100 mg/d,아탁벌타정20 mg/d,보라포고0.25/차,2차／d,구복).비교치료전화치료후4주혈청HMGB1、OPG화MIF수평.결과 치료전,역손반괴조중량아조혈청HMGB1、OPG화MIF함량균명현고우은정반괴조,차이유현저통계학의의(균P＜0.01)；량아조중혈청HMGB1、OPG화MIF함량차이무통계학의의(균P＞0.05).치료후4주,PAS조중혈청HMGB1,OPG화MIF함량균명현저우AS조,차각지표하강폭도균고우AS조,차이유현저통계학의의(균P＜0.01).결론 혈청HMGB1、OPG화MIF균삼여뇌경사환자동맥죽양경화적진정,가작위평고경동맥죽양경화반괴불은정성적예측인자,PAS삼련요법가유효강저기혈청농도,구유경강적항염작용,가제고역손반괴적은정성.
Objective To observe the changes of levels of high-mobility group box 1protein (HMGB1),osteoprotegerin(OPG) and macrophage migration inhibitory factor(MIF) in patients with acute cerebral infarction(ACI) and the influence of combination therapy of probucol,aspirin and statins drugs (PAS).Methods According to the results of carotid artery ultrasound,150 cases of patients with ACI were divided into carotid stable plaque group (n =50) and carotid vulnerable plaque group(n =100).Stable plaque group was considered as control group.100 cases with carotid vulnerable plaque were randomly divided into aspirin and statins drugs (AS) group ( n =50,aspirin 100 mg/d,atorvastatin 20 rag/d,oral) and PAS group (n =50,aspirin 100 mg/d,atorvastatin 20 mg/d,probucol 0.25/time,2 times/day,oral).Serum levels of HMGB1,OPG and MIF were detected in all patients before treatment and four weeks after drug therapy.Results Before treatment,serum HMGB1,OPG and MIF levels in two subgroups of vulnerable plaque group( AS group and PAS group) were higher than stable plaque group( control group) ( all P ＜ 0.01),there were no significantly differences of HMGB1,OPG and MIF between AS group and PAS group (all P ＞ 0.05 ).Four weeks later,levels of HMGB1,OPG and MIF in patients who treated with probucol,aspirin and statins drugs (PAS) were lower significantly than that in patients who treated with aspirin and statins drugs(AS),and the decrease of levels of HMGB1,OPG and MIF were obviously higher in PAS group than that in AS group ( all P ＜ 0.01).Conclusions HMGB1,OPG and MIF may be involved in the pathological process in patients with acute cerebral infarction,may be used as the prediction factor of instable atherosclerosis plaque.PAS triple therapy might effectively reduce serum levels of HMGB1,OPG and MIF,might have the stronger anti-inflammation function,could stabilize the atherosclerosis vulnerable plaque.
